Given Imaging Ltd. Announces Results of 2009 Annual Shareholders’ Meeting

YOQNEAM, ISRAEL--(Marketwire - August 12, 2009) - Given Imaging Ltd. (NASDAQ: GIVN) today announced the results of its annual shareholders’ meeting which was held yesterday in Yoqneam, Israel. A total of 22,945,379 shares, or approximately 78.4% of the total number of shares entitled to vote at the meeting, were represented, and all five proposed resolutions were approved.

The following resolutions were approved:

1. Re-election of Israel Makov, Nachum (Homi) Shamir, Doron Birger, Arie Mientkavich, Dennert O. Ware and Prof. Anat Leowenstein as directors of the company until the next Annual General Meeting of Shareholders; 2. Compensation of the President and Chief Executive Officer of the Company; 3. Adoption of the Company’s 2009 Equity Incentive Plan; 4. Extending the expiration term of certain stock options previously granted to directors of the Company (other than the external directors under Israeli law) under the Company’s 2006 Equity Incentive Plan with an expiration date of five years from the date of grant, by two additional years until the seventh anniversary of the date of grant; and 5. Re-appointment Somekh Chaikin, a member of KPMG International, as the Company’s independent auditors until the Company’s next Annual General Meeting of Shareholders and to authorize the Company’s Audit Committee and Board of Directors to determine their remuneration. 

The board of directors wishes to thank shareholders for participating and voting at this annual general meeting.

About Given Imaging

Given Imaging has advanced gastrointestinal diagnosis by developing innovative, patient-friendly tools based on its PillCam® Platform. PillCam capsule endoscopy provides physicians with natural images of the small intestine via PillCam® SB, the esophagus through PillCam® ESO, and the colon with PillCam® COLON [PillCam COLON is not cleared for use in the USA]. The PillCam capsules are miniature video cameras that patients ingest. Given Imaging’s other capsule products include Agile™ patency capsule, to verify intestinal patency, and Bravo®, the only wireless, catheter-free, 48-hour pH test commercially available for pH testing to assess gastroesophageal reflux disease (GERD). Given Imaging’s products use cutting-edge, wireless technology and advanced software to enable gastroenterologists to better diagnose disease of the esophagus, small bowel and colon and more accurately treat patients. All Given Imaging products allow patients to maintain normal activities. Since 2001, more than one million PillCam® video capsules have helped physicians evaluate patients for GI disorders. Given Imaging’s headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel, with operating subsidiaries in the United States, Germany, France, Japan, Australia and Singapore. For more information, please visit http://www.givenimaging.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as “may,” “anticipates,” “estimates,” “expects,” “intends,” “plans,” “believes,” and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (3) our success in implementing our sales, marketing and manufacturing plans, (4) protection and validity of patents and other intellectual property rights, (5) the impact of currency exchange rates, (6) the effect of competition by other companies, (7) the outcome of significant litigation, (8) our ability to obtain reimbursement for our product from government and commercial payors, (9) quarterly variations in operating results, (10) the possibility of armed conflict or civil or military unrest in Israel, (11) the impact of global economic conditions, and (12) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as “Risk Factors,” “Cautionary Language Regarding Forward-Looking Statements” and “Operating Results and Financial Review and Prospects” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2008. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except for the Company’s ongoing obligations to disclose material information under the applicable securities laws, it undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.